Research
Novel ADC Could Expand Treatment Options in Ovarian Cancer
The Brief
- Updated results from the FONTANA trial were presented at the annual European Society for Medical Oncology (ESMO) congress.
- The investigational antibody-drug conjugate (ADC) torvutatug samrotecan showed promising activity in ovarian cancer.
Why it matters
If confirmed in further studies, this investigational ADC could expand treatment options for ovarian cancer. The available source excerpt does not give detailed efficacy figures.
Who’s affected
- oncologists and clinicians treating ovarian cancer
- ovarian cancer patients
(MedPage Today) -- Updated results from the FONTANA trial presented at the annual European Society for Medical Oncology congress showed promising activity with the investigational antibody-drug conjugate (ADC) torvutatug samrotecan (torvu-sam...